Trenbolone: long ester
Trenbolone Enanthate
Trenbolone enanthate is a slowly released trenbolone ester studied in rats; the cited sources report no half-life for it in people. The app's half-life is about 8 days.
Trenbolone Enanthate after one dose: 50% at ~8 days, 25% at 16 days, 12.5% at 24 days.
Drawn from the half-life in the app's model, ~8 days. The model's figures
- Compound
- Trenbolone Enanthate
- Symbol
- TRE
- Family
- Other steroids
- Parts
- 14
- References
- 15
- Checked
- Last reviewed . Sources are listed below.
Overview
Trenbolone enanthate is an ester of trenbolone; Yarrow and colleagues (American Journal of Physiology Endocrinology and Metabolism, 2011) call trenbolone "a potent testosterone analog" and describe trenbolone enanthate as "a slowly released trenbolone ester".1 A search of PubMed on 16 November 2026 for trenbolone enanthate in the title or summary text returned 10 records. Six describe rat studies,1,3,8,9,10,11 one is a case report of liver injury,2 one is a hair analysis in two men,4 and two are laboratory methods for detecting steroid esters or screening supplements.12,13 In the text read for each record, none of the 10 reports a trial of trenbolone enanthate in people.
The figures row above is the app's, not taken from the cited studies: the app lists trenbolone enanthate as a long-ester trenbolone with a half-life of about 8 days (192 hours), 95% bioavailability, a typical dose of 50 to 400 mg per week, the intramuscular route and a time to peak of about 48 hours. None of the sources cited here reports any of those five figures for trenbolone enanthate in people.
How it works
Sources in this part
In the 2011 rat study, Yarrow and colleagues write that trenbolone "does not undergo 5α-reduction to more potent metabolites", unlike testosterone, which is converted to dihydrotestosterone (DHT).1 Citing earlier work, they write that trenbolone possesses "three times the affinity of testosterone for the AR", the androgen receptor, and that the mechanism behind its muscle effect "requires further clarification".1 They also write that "it has been reported that trenbolone does not undergo aromatization due to its 3-oxotriene structure", although "conflicting reports exist regarding the influence of trenbolone on circulating estrogens in mammalian species".1 McCoy and colleagues (Bone, 2012) write that trenbolone "has agonist action at the progesterone receptor".3 In the pilot experiment of the 2011 study (5 rats per group), trenbolone enanthate lowered serum testosterone in intact rats: within 10 days of two weekly injections of 7.0 mg per animal it was 80% lower (2.55 ± 0.46 versus 0.49 ± 0.07 ng/ml) and DHT was 70% lower than in vehicle-treated intact rats.1
Pharmacokinetics
A search of PubMed on 16 November 2026 for trenbolone with pharmacokinetic or half-life in the title or summary text returned 9 records, whose titles concern cattle manure, steers, fish, runoff, horse plasma, a plasma-binding method and hormones in meat production. The cited sources give no half-life for trenbolone enanthate; the search used only those terms and each of its 9 records was judged by title alone, so it does not rule out reports elsewhere. The one serum trenbolone time course among the cited sources is in rats, from the 2011 pilot experiment, sampled every 2 days for 10 days in 5 rats per group.1
| Parameter | The app's figure | Figure in a cited source | Reference |
|---|---|---|---|
| Half-life | ~8 days (192 hours) | None reported in the cited sources | Not applicable |
| Time to peak | ~48 hours | Rats, 7.0 mg per animal into muscle at baseline and 7 days later, blood sampled every 2 days: peak serum trenbolone of 46.0 ± 5.6 ng/ml on day 9, which the authors describe as occurring within 48 h of the second injection; this is a second-dose peak with the first-injection peak not reported, so it is not a single-dose time to peak and is not comparable with the app's figure1 | Yarrow 20111 |
| Duration of activity | ~14 days | In rats, serum trenbolone was elevated throughout the 7 days after an injection; the same research group says the enanthate esters give elevated concentrations "for at least 7 days"1,3 | Yarrow 2011; McCoy 20121,3 |
| Bioavailability | ~95% | None reported in the cited sources | Not applicable |
| Route | Intramuscular | Rat studies injected into the quadriceps muscle once weekly1 | Yarrow 20111 |
Values from the Milligram app's model.
- Half-life
- ~8 days
- Bioavailability
- 95%
- Typical dose
- 50–400 mg/week
- Route
- IM
- Time to peak
- ~48 h
Sources in this part
The chart below is an illustrative model, not a measured curve: it uses the app's half-life of 192 hours and time to peak of 48 hours, neither sourced for people, with the weekly interval used in the rat studies.1 The dose range of 25 to 400 mg is the app's as well; the rat studies gave 0.5 to 7.0 mg per animal, to rats of about 270 g at baseline in the intact-rat experiment.1
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: every 7 days (rat injection interval)1.
An illustration from a pharmacokinetic model using a half-life of 192 hours (8 days). It is not a measured level or a suggested dose.
Human studies
The reports below in people name trenbolone or its enanthate; only the first two name the enanthate. None is a controlled trial of trenbolone enanthate.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Boks and colleagues, 20172 | Case report from an outpatient clinic, with a liver biopsy.2 | One young amateur bodybuilder with jaundice and loss of appetite.2 | Dose and length of use not given in the PubMed record.2 | Cholestatic hepatitis; the tests made it "likely" that the injectable steroid trenbolone enanthate caused it.2 |
| Kintz and Gheddar, 20264 | Two forensic cases; body hair tested by chromatography with tandem mass spectrometry.4 | Two men investigated for sexual assault; the first confessed to steroid use for 3 years.4 | Doses not given.4 | Case 1: trenbolone enanthate 0.8 pg/mg, trenbolone 9 pg/mg, testosterone enanthate 102 pg/mg, testosterone 0.9 pg/mg, metandienone 4 pg/mg. Case 2: trenbolone 0.5 pg/mg, with no trenbolone enanthate listed.4 |
| Krombholz and colleagues, 2026 (trenbolone, not the enanthate)5 | Urinary excretion study by three routes.5 | Healthy male volunteers; number not given in the PubMed record.5 | 10 mg of trenbolone by mouth, on the skin or in the cheek; urine for one week.5 | Buccal route: faster elimination; transdermal route: prolonged detectability, compared with oral.5 |
| Bonenti and colleagues, 2026 (injectable trenbolone, ester not named)6 | Cross-sectional comparison within the Global Drug Survey 2024.6 | 1,146 men who had used anabolic-androgenic steroids in the past year: 237 with and 909 without injectable trenbolone.6 | Self-reported use; no dose analysed.6 | Self-reported concerns, perceived as resulting from the person's own steroid use: negative impact on the heart 54.4% versus 31.2% and on the liver 42.2% versus 22.4% (trenbolone versus non-trenbolone group, both p<0.001). The trenbolone group also reported more past-year oral (79.7% versus 38.4%) and injectable (99.2% versus 59.3%) steroid use.6 |
| Piatkowski and colleagues, 2024 (trenbolone, ester not named)7 | Online survey; purposive and snowball sampling.7 | 282 males using anabolic-androgenic steroids; 93 currently using trenbolone.7 | Self-reported trenbolone dose; values not given in the PubMed record.7 | After controlling for age and BMI, trenbolone dose was associated with higher verbal aggression (p=0.045), "particularly at higher doses". The study also hypothesised a link with psychological distress, and the PubMed record reports no distress result.7 |
Case report and hair analysis
Boks and colleagues (Journal of Sports Sciences, 2017) describe a young amateur bodybuilder referred to their outpatient clinic with jaundice and loss of appetite due to cholestatic hepatitis.2 Their PubMed record says additional tests including a liver biopsy "made it likely" that the hepatitis was caused by injectable trenbolone enanthate.2 The record does not state the dose, the length of use or whether other substances were taken, and a single case cannot show how often this happens.2 Kintz and Gheddar (Journal of Analytical Toxicology, 2026) found trenbolone enanthate at 0.8 pg/mg in the pubic hair of the first of two men investigated for sexual assault, alongside testosterone enanthate at 102 pg/mg and trenbolone at 9 pg/mg.4
Studies in rats
Six of the 10 PubMed records for trenbolone enanthate are rat studies, and all six list J. F. Yarrow, D. T. Beck or S. E. Borst among their authors; the four with funding statements in the full text name Veterans Affairs awards.1,3,8,9
| Study and year | Design | Animals | Dose and length | Main result |
|---|---|---|---|---|
| Yarrow and colleagues, 20111 | Three experiments: a pilot of delivery and hormone suppression, orchiectomized rats and intact rats.1 | Male F344 rats aged 3 months; 10 per group (orchiectomy experiment), 5 per group (intact and pilot experiments).1 | 1.0, 3.5 or 7.0 mg per week (orchiectomized) and 0.5 or 1.0 mg per week (intact), into muscle, 29 days; testosterone enanthate 7.0 mg per week as comparator.1 | Orchiectomized rats: levator ani/bulbocavernosus muscle 35 to 40% above sham at every dose; lowest doses kept prostate mass and hemoglobin at sham levels, while testosterone enanthate raised prostate mass 84% and high-dose trenbolone enanthate 68%; moderate and high doses raised hemoglobin by about 8 to 10%. Intact rats: muscle 21 to 38% above sham, prostate mass 59% above sham with testosterone enanthate and at sham level with 1.0 mg per week of trenbolone enanthate.1 |
| McCoy and colleagues, 20123 | Randomised comparison in skeletally mature orchiectomized rats.3 | 40 male F344/Brown Norway rats aged 10 months, 10 per group.3 | 1.0 mg per week into muscle for 5 weeks; testosterone enanthate 7.0 mg per week as comparator.3 | Both completely prevented the orchiectomy-induced loss of total and trabecular bone mineral density at the distal femoral metaphysis; femoral neck strength 28% above orchiectomy with trenbolone enanthate but not testosterone enanthate; at the femoral diaphysis trenbolone enanthate did not preserve total bone area, and total bone mineral content was 7% below sham, cortical content 6% and cortical area 6% (p<0.05); testosterone enanthate nearly doubled prostate mass, trenbolone enanthate did not (nonsignificant 20% reduction versus sham); hemoglobin 10 to 11% above both sham and orchiectomy with both androgens (p<0.01), including trenbolone enanthate at 1.0 mg per week, the dose the 2011 authors call low; kidney mass 18 to 23% above orchiectomy with both; muscle mass rose similarly with both.3 |
| Beck and colleagues, 20148 | Seven groups, including trenbolone enanthate with and without the aromatase inhibitor anastrozole.8 | 73 male Fisher 344 rats aged 10 months.8 | 1.0 mg per week; euthanized at day 28.8 | Testosterone enanthate and trenbolone enanthate suppressed cancellous bone turnover similarly and fully prevented orchiectomy-induced cancellous bone loss; in trenbolone-treated animals anastrozole produced no discernible effects on cancellous bone turnover or bone volume.8 |
| Yarrow and colleagues, 20129 | Gonadectomized male rats given graded trenbolone enanthate doses, with testosterone enanthate as comparator.9 | Male F344 rats aged 3 months, 10 per group.9 | 1.0, 3.5 or 7.0 mg per week into muscle; sacrificed at day 28.9 | Trenbolone enanthate prevented the gonadectomy-induced rise in serum adiponectin (p≤0.001); the low dose restored it to sham levels and higher doses reduced it below sham.9 |
| Dalbo and colleagues, 201710 | Comparison of sham, orchiectomy, testosterone and trenbolone groups.10 | 41 Fisher 344 rats aged 10 months.10 | 1.0 mg per week; 29 days.10 | Levator ani/bulbocavernosus fibre cross-sectional area 94% higher and satellite cell numbers 178% higher than orchiectomy alone; myostatin protein increased 169%; myonuclear number per fibre did not differ between conditions (p = .948). Testosterone enanthate 7.0 mg per week gave similar results (fibre area 102%, satellite cells 181%, myostatin 159% higher).10 |
| Mumford and colleagues, 201811 | Part of a study of ageing muscle and Wnt signalling; orchiectomized rats given testosterone enanthate, trenbolone enanthate or vehicle.11 | Male Fischer 344 rats aged 10 months, 10 to 11 per group.11 | Dose not given in the PubMed record; 4 weeks.11 | Both androgens increased Wnt5a protein in the levator ani/bulbocavernosus muscle compared with orchiectomy only.11 |
Deeper analysis: Yarrow and colleagues, American Journal of Physiology Endocrinology and Metabolism, 2011
The authors tested the hypothesis that trenbolone enanthate "might prevent orchiectomy-induced losses in muscle and bone and visceral fat accumulation without increasing prostate mass or resulting in adverse hemoglobin elevations".1 They used male F344 rats aged 3 months, with 10 animals per group in the orchiectomy experiment and 5 per group in the intact-animal and pilot experiments, and weekly intramuscular injections for 29 days.1 Orchiectomy cut the mass of the levator ani/bulbocavernosus muscle complex by 59% against sham; every androgen treatment prevented that and added 35 to 40% above sham.1 Total bone mineral density at the distal femur was higher with the lowest, moderate and highest doses by 6, 9 and 9% against orchiectomy, and trabecular mineral density by 37, 45 and 55%, but trenbolone enanthate did not fully restore trabecular values to sham.1 Femoral midshaft strength measures did not differ between groups, and weight gain in every androgen-treated group ended 30 to 50% below sham.1 At the higher doses the prostate, kidney and hemoglobin measures rose: prostate mass was 84% above sham with testosterone enanthate and 68% above with high-dose trenbolone enanthate, kidney mass was about 19% above sham with the moderate and high doses, and whole-blood hemoglobin was about 8 to 10% above sham with those doses.1 The authors state limits in their own words: "we did not directly evaluate the possibility that TREN may initiate or accelerate prostate cancer growth", circulating estrogens could not be measured, and "the long-term SARM-like potential of TREN remains to be determined".1 The work was supported by a Veterans Department Merit Award to the last author, S. E. Borst, and the authors declared no conflicts of interest.1
Deeper analysis: McCoy and colleagues, Bone, 2012
This study asked whether low-dose trenbolone enanthate protects bone in skeletally mature orchiectomized rats without raising prostate mass or hemoglobin.3 Forty rats aged 10 months were randomised to sham, orchiectomy, orchiectomy with testosterone enanthate 7.0 mg per week or orchiectomy with trenbolone enanthate 1.0 mg per week, injected weekly for 5 weeks after a week of recovery.3 Both treatments completely prevented the orchiectomy-induced fall in total and trabecular bone mineral density at the distal femur, and femoral neck strength was 28% higher with trenbolone enanthate than with orchiectomy (p<0.05) while testosterone enanthate did not change it.3 Testosterone enanthate nearly doubled prostate mass against sham (p<0.05), whereas trenbolone enanthate gave a nonsignificant 20% reduction, a prostate 64% below that of the testosterone group (p<0.01).3 The authors note that "both TREN and high-dose TE resulted in similar elevations in hemoglobin concentrations", and that further studies are needed to evaluate other potential side effects.3 Funding was a Veterans Affairs Merit Award and a Career Development Award, and the paper states that the funding agency "had no role in the study design, collection, analysis, preparation or submission of this manuscript".3
Doses reported in studies
The doses of trenbolone enanthate in the cited studies are all in rats, in milligrams per animal per week into muscle: 0.5, 1.0, 3.5 and 7.0 mg, against 7.0 mg of testosterone enanthate as the supraphysiological comparator; the rats weighed about 270 g at baseline in the 2011 study's intact-rat experiment.1,9 The authors of the 2011 study call 1.0 mg per week the "low" dose and 7.0 mg per week the "high" dose.1 The two human reports that name the enanthate give no dose, and Krombholz and colleagues, the human study of trenbolone itself, used 10 mg of trenbolone by mouth, on the skin or in the cheek, not the enanthate.2,4,5 The app's typical dose of 50 to 400 mg per week appears in none of the cited sources.
Side effects reported
For trenbolone enanthate itself in people, the cited sources report one case, the cholestatic hepatitis described by Boks and colleagues.2 Other human reports concern trenbolone without naming the ester.6,7 In the Global Drug Survey 2024 comparison by Bonenti and colleagues (Drug and Alcohol Review, 2026), men who had used injectable trenbolone in the past year (n = 237) more often reported, as concerns they perceived as resulting from their steroid use, anger or aggression (21.1% versus 9.2%), depression or low mood (23.6% versus 12.0%), hair loss (42.6% versus 27.6%), gynecomastia (32.5% versus 20.6%) and acne (32.5% versus 24.4%) than men who had used other steroids (n = 909).6 Decreased fertility, 26.2% versus 19.0%, was reported more often (p = 0.015), while reduction and increase in breast size did not differ between the groups (0.4% versus 0.4%, and 3.4% versus 3.4%).6 The authors write that the data are "self-reported, cross-sectional", "cannot establish causality", and represent "perceived effects rather than clinically verified diagnoses", and that they did not analyse dose, cycle length or stacking.6 The trenbolone group also reported more other steroid use in the past year, oral 79.7% versus 38.4% and injectable 99.2% versus 59.3%, and the authors write that its "substantially greater oral AAS involvement likely compounds this effect" on the liver.6 One author was supported by a National Health and Medical Research Council Investigator Grant and the authors declared no conflicts of interest.6 In rats, Yarrow and colleagues (2011) report hemoglobin about 8 to 10% above sham and kidney mass about 19% above sham at moderate and high doses, and McCoy and colleagues (2012) report hemoglobin 10 to 11% above both sham and orchiectomy at 1.0 mg per week, similar to high-dose testosterone enanthate.1,3
Bloodwork and markers
The app lists total testosterone, prolactin, hematocrit, lipids and kidney function as markers for trenbolone enanthate. In the cited rat studies, serum testosterone and DHT were lower in treated intact rats, whole-blood hemoglobin and kidney mass were higher at moderate and high doses in 3-month-old rats, hemoglobin was also 10 to 11% higher at 1.0 mg per week in 10-month-old rats, and serum adiponectin was below sham at the higher doses.1,9 None of the cited sources reports prolactin or lipid measurements for trenbolone enanthate, or any bloodwork in people given it. Tretzel and colleagues (Journal of Pharmaceutical and Biomedical Analysis, 2014) developed a dried blood spot assay for eight steroid esters including trenbolone enanthate, which they say allows "an unequivocal proof of the administration of conjugates of exogenous testosterone and its derivatives"; no sample from a person given trenbolone enanthate is described in the PubMed record.12 Saadabadi and colleagues (Iranian Journal of Pharmaceutical Research, 2022) built a thin-layer chromatography method for ten anabolic steroids including trenbolone enanthate and screened 50 whey protein products for athletes (9 tablets and 41 powders) from the retail market in Tehran, May 2020 to May 2021; "none of the samples screened positive", and the result was reconfirmed by a second method, LC-MS/MS.13
Regulatory and anti-doping status
Sources in this part
The World Anti-Doping Agency's 2026 Prohibited List names trenbolone among the anabolic androgenic steroids in section S1.1, which it lists as prohibited at all times, in and out of competition.14 The list applies S1.1 to the substances named "and other substances with a similar chemical structure or similar biological effect(s) including their esters" when administered exogenously.14 In the United States, 21 CFR 1308.13(f) lists trenbolone (17β-hydroxyestr-4,9,11-trien-3-one) among the anabolic steroids in Schedule III, "including its salts, esters and ethers", unless specifically excepted or listed in another schedule.15 The sources cited here do not cover the status of trenbolone enanthate in other countries, and a DailyMed search on 16 November 2026 found 0 labels for it.
What is not known
Sources in this part
- The cited sources report no half-life, bioavailability or time to peak for trenbolone enanthate in people.
- The cited sources report no trial of trenbolone enanthate in people, and the human reports that name it are a single case and a hair analysis.
- Whether the rat results on bone, muscle, prostate and hemoglobin apply to people is not tested in the cited sources.1
- The surveys of men who use trenbolone do not name the ester, dose or cycle, and their authors state they cannot establish causality.6
Frequently asked questions
What is the half-life of trenbolone enanthate?
The app lists the half-life of trenbolone enanthate as about 8 days (192 hours). The cited sources report no half-life for the ester, and the search of PubMed behind that statement was limited to two terms and judged by title. A rat study measured serum trenbolone for 10 days after weekly 7.0 mg injections, with a peak on day 9, after the second injection.1
Is trenbolone enanthate banned by WADA?
Is trenbolone enanthate a controlled substance in the United States?
Trenbolone is listed in 21 CFR 1308.13(f), the anabolic steroids entry in Schedule III, which covers its salts, esters and ethers unless specifically excepted or listed in another schedule.15
Does trenbolone enanthate aromatize?
What does trenbolone enanthate do in rats?
In orchiectomized rats given 1.0 to 7.0 mg per week for 29 days, it raised levator ani/bulbocavernosus muscle mass 35 to 40% above sham and partly protected bone density.1 At 1.0 mg per week it kept prostate mass at sham levels, while 7.0 mg per week raised it 68%.1 At 3.5 and 7.0 mg per week hemoglobin was about 8 to 10% above sham and kidney mass about 19% above, and weight gain in every androgen-treated group ended 30 to 50% below sham.1 In 10-month-old rats given 1.0 mg per week, hemoglobin was 10 to 11% above sham and distal femoral bone density loss was completely prevented, while diaphysis bone mineral content and cortical area were 6 to 7% below sham.3
Has trenbolone enanthate been studied in people?
What side effects of trenbolone are reported in people?
In a Global Drug Survey 2024 comparison, men who used injectable trenbolone reported concerns about a negative impact on the heart more often than men who used other steroids, 54.4% versus 31.2%, and on the liver, 42.2% versus 22.4%.6 The trenbolone group also reported more past-year oral (79.7% versus 38.4%) and injectable (99.2% versus 59.3%) steroid use.6 The authors say the data are self-reported and cannot establish causality, and the paper does not name the ester.6
What is the difference between trenbolone enanthate and trenbolone acetate?
Both are esters of trenbolone, and the app lists a half-life of about 60 hours for the acetate and about 192 hours for the enanthate. The cited sources report no half-life for either ester, so a measured difference is not stated here.
Guides, tools and comparisons
References
- Yarrow JF, et al. 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate. Am J Physiol Endocrinol Metab 2011. PMC6189634
- Boks MN, Tiebosch AT, van der Waaij LA. A jaundiced bodybuilder: Cholestatic hepatitis as side effect of injectable anabolic-androgenic steroids. J Sports Sci 2017. PMID 27937337
- McCoy SC, et al. 17β-Hydroxyestra-4,9,11-trien-3-one (Trenbolone) preserves bone mineral density in skeletally mature orchiectomized rats without prostate enlargement. Bone 2012. PMC8392872
- Kintz P, Gheddar L. Detection of anabolic-androgenic steroids in body hair from two individuals investigated for sexual assault. J Anal Toxicol 2026. PMID 42750152
- Krombholz S, et al. The influence of the route of drug administration on the metabolic profile of trenbolone in doping control urine samples. Steroids 2026. PMID 41224119
- Bonenti B, et al. The Trenbolo(g)ne Sandwich: An International Study Comparing Health Harms Among Men Who Use Anabolic-Androgenic Steroids With and Without Trenbolone. Drug Alcohol Rev 2026. PMC13112052
- Piatkowski T, et al. Examining the association between trenbolone, psychological distress, and aggression among males who use anabolic-androgenic steroids. Int J Drug Policy 2024. PMID 39486244
- Beck DT, et al. Influence of aromatase inhibition on the bone-protective effects of testosterone. J Bone Miner Res 2014. PMC8366408
- Yarrow JF, et al. Influence of androgens on circulating adiponectin in male and female rodents. PLoS One 2012. PMC3468547
- Dalbo VJ, et al. Testosterone and trenbolone enanthate increase mature myostatin protein expression despite increasing skeletal muscle hypertrophy and satellite cell number in rodent muscle. Andrologia 2017. PMID 27246614
- Mumford PW, et al. Cross talk between androgen and Wnt signaling potentially contributes to age-related skeletal muscle atrophy in rats. J Appl Physiol 2018. PMID 29722624
- Tretzel L, et al. Use of dried blood spots in doping control analysis of anabolic steroid esters. J Pharm Biomed Anal 2014. PMID 24713476
- Saadabadi Z, et al. Simultaneous Analysis and Efficient Separation of Anabolic Androgenic Steroids in Dietary Supplement by a Validated HPTLC Method. Iran J Pharm Res 2022. PMC10024326
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. In force 1 January 2026. WADA Prohibited List 2026
- US Drug Enforcement Administration. 21 CFR 1308.13, Schedule III. Electronic Code of Federal Regulations. 21 CFR 1308.13